MARKET

PRPO

PRPO

PRECIPIO
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.050
+0.020
+0.66%
Closed 19:30 07/29 EDT
OPEN
3.030
PREV CLOSE
3.030
HIGH
3.180
LOW
2.950
VOLUME
400.82K
TURNOVER
--
52 WEEK HIGH
9.18
52 WEEK LOW
1.200
MARKET CAP
69.26M
P/E (TTM)
-5.1520
1D
5D
1M
3M
1Y
5Y
BRIEF-Precipio Announces Preliminary Unaudited Q2-2021 Revenues Of $2.3 Mln
reuters.com · 1d ago
Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M
Specialty diagnostics Company Precipio, Inc. (NASDAQ: PRPO), announces preliminary unaudited revenues for Q2-2021 demonstrating continued substantial YoY and quarterly growth.
GlobeNewswire · 1d ago
Thinking about buying stock in Allied Esports Entertainment, Frontline, Naked Brand, Chevron, or Precipio?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AESE, FRO, NAKD, CVX, and PRPO.
PR Newswire - PRF · 07/02 13:31
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 07/01 21:35
Precipio terminates its equity line with Lincoln Park
As part of management’s review of its current financing arrangements, Precipio ([[PRPO]] +2.0%) terminated the equity line financing structure it had in place with Lincoln Park Capital.The equity line was used for funding
Seekingalpha · 06/15 15:55
BRIEF-Precipio Terminates Its Equity Line
reuters.com · 06/15 15:09
Clearside Biomedical, Eloxx Pharmaceuticals leads healthcare gainers; PDS Biotechnology, Sage Therapeutics among major losers
Gainers: Clearside Biomedical (CLSD) +30%, Eloxx Pharmaceuticals (ELOX) +15%, Fusion Pharmaceuticals (FUSN) +14%, Precipio (PRPO) +14%, Ocugen (OCGN) +11%.Losers: PDS Biotechnology (PDSB) -27%, Sage Therapeutics (SAGE) -16%, NeuroBo Pharmaceuticals (NRBO) ...
Seekingalpha · 06/15 15:02
Precipio Terminates Equity Line From Lincoln Park Capital
MT Newswires · 06/15 13:04
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRPO. Analyze the recent business situations of PRECIPIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRPO stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 25
Institutional Holdings: 1.18M
% Owned: 5.21%
Shares Outstanding: 22.71M
TypeInstitutionsShares
Increased
5
399.91K
New
2
16.95K
Decreased
4
40.24K
Sold Out
2
59.30K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.96%
Healthcare Equipment & Supplies
+0.72%
Key Executives
Chairman/Director
Richard Sandberg
President/Chief Executive Officer/Director
Ilan Danieli
Chief Financial Officer
Carl Iberger
Chief Operating Officer
Ahmed Sabet
Other
Ori Karev
Other
Stephen Miller
Director
Ronald Andrews
Director
David Cohen
Director
Douglas Fisher
Independent Director
Jeffrey Cossman
Independent Director
Kathleen LaPorte
No Data
About PRPO
Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market. The Company’s platform is designed to provide physicians and their patients access to necessary technology in order to provide diagnoses. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a proprietary culture media that addresses the problem of selective culturing-by creating a universal media that enables simultaneous culturing of hematopoietic cell lineages. ICP is a specimen enrichment technology that increases the sensitivity of molecular based tests. The Company has developed a screening panel for genes in one rapid scanning panel, HemeScreen.

Webull offers kinds of Precipio Inc stock information, including NASDAQ:PRPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRPO stock methods without spending real money on the virtual paper trading platform.